ArticleJournal of the American Academy of Dermatology2021
Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study.
Article in Journal of the American Academy of Dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study.Frontiers in immunology · 2025Article
- A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus.Vaccines · 2024Review
- Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.Frontiers in medicine · 2023Article
- Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.Frontiers in medicine · 2023Review
- New-onset pemphigus vegetans and pemphigus foliaceus after SARS-CoV-2 vaccination: A report of 2 cases.JAAD case reports · 2022Article
- Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study.Dermatologic therapy · 2022Article
- Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.Journal of clinical medicine · 2022Review
- SARS-CoV-2 infections in patients with autoimmune blistering disorders: A case series and retrospective analysis.JAAD international · 2022Article
- COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.Dermatologic therapy · 2022Article
- Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?Frontiers in medicine · 2022Article
- Off-Label Uses of Rituximab in Dermatology.Current dermatology reports · 2022Review
- Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?Frontiers in medicine · 2022Article
- Patient Quality of Life Improvement in Bullous Disease: A Review of Primary Literature and Considerations for the Clinician.Clinical, cosmetic and investigational dermatology · 2022Review
- COVID-19 outcomes in patients with autoimmune blistering disease.The British journal of dermatology · 2021Article
- Pemphigus-The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic.Biomedicines · 2021Review
- Epidemiology of Pemphigus.JID innovations : skin science from molecules to population health · 2021Review
- Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report.Frontiers in medicine · 2021Article
- Article
- Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.Frontiers in immunology · 2021Article
- COVID-19: The experience from Iran.Clinics in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.